U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. Vaccinia Immune Globulin Intravenous (Human)
  1. Approved Blood Products

Vaccinia Immune Globulin Intravenous (Human)

STN: BL 125109
Proper Name: Vaccinia Immune Globulin Intravenous (Human)
Tradename: None
Manufacturer: Cangene Corp, License #1201
Indications:

  • Treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination
    • Eczema vaccinatum
    • Progressive vaccinia
    • Severe generalized vaccinia
    • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions
    • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard.

Product Information

Supporting Documents

Back to Top